Nutrimedy Announces First Patient Enrolled in Feasibility Study at University of Kansas Medical Center
Retrieved on:
Monday, August 9, 2021
Technology, Decision-making, Disease, Health, HF, Diet, CEO, Heart failure, Moyamoya disease, Type 2 diabetes, Diuresis, Boston Scientific, University, University of Kansas Medical Center, Atrial fibrillation, Associate, Children's Mercy Hospital, Chronic kidney disease, Patient, Sodium, Diagnosis, Malnutrition, Hospital, Nutrient, Vasoconstriction, Medical device, Dietary supplement, Pharmaceutical industry
The study will assess the ability to gather patient dietary intake through Nutrimedy as well as evaluate sensor data from the HeartLogic HF Diagnostic compared to dietary intake.
Key Points:
- The study will assess the ability to gather patient dietary intake through Nutrimedy as well as evaluate sensor data from the HeartLogic HF Diagnostic compared to dietary intake.
- All participants will be enrolled from a single clinic and the study is estimated to take four to six months total.
- Heart failure affects around 6.5 million people in the U.S. and is expected to climb to 8 million by 2030.
- "Combining heart failure diagnostic data with the expertise of professionals at Nutrimedy puts the power of technology literally at the patient's fingertips.